Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Aragane

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Brain Research. Cognitive Brain Research|October 1, 1993
Chronometrical analysis of event-related potentials and reaction time in patients with multiple lacunar infarctsH Tachibana, K Toda, K Aragane, et al.
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica|March 21, 1998
[Effect of F-1394, a potent and selective inhibitor of acyl-CoA:cholesterol acyltransferase (ACAT), on esterification of cholesterol and basolateral secretion of cholesteryl ester in Caco-2 cells]J Kusunoki, K Aragane, T Kitamine, et al.
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|April 1, 1997
[Hypolipidemic action of F-1394, an acyl-CoA: cholesterol acyltransferase (ACAT) inhibitor, in high-fat diet fed beagle dogs]J Kusunoki, K Aragane, T Kitamine, et al.
Atherosclerosis|August 14, 2001
Effect of F-1394, an acyl-CoA:cholesterol acyltransferase inhibitor, on atherosclerosis induced by high cholesterol diet in rabbitsK Aragane, K Kojima, K Fujinami, et al.
Japanese Journal of Pharmacology|May 21, 1998
Effects of F-1394, an acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor, on ACAT activity in HepG2 cells and on hepatic secretion of lipids in Triton WR-1339-induced hyperlipidemic rats: possible role of hepatic ACAT in very low density lipoprotein secretionK Aragane, J Kusunoki, T Kitamine, et al.
Lancet (London, England)|December 10, 1999
Fever, cough, and nodules on anklesK Aragane, N Akao, T Matsuyama, et al.
Japanese Journal of Pharmacology|September 1, 1995
Hypocholesterolemic action and prevention of cholesterol absorption via the gut by F-1394, a potent acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor, in cholesterol diet-fed ratsJ Kusunoki, K Aragane, T Kitamine, et al.
British Journal of Pharmacology|August 7, 2001
Direct effect of an acyl-CoA:cholesterol acyltransferase inhibitor, F-1394, on atherosclerosis in apolipoprotein E and low density lipoprotein receptor double knockout miceT Chiwata, K Aragane, K Fujinami, et al.
Circulation|May 31, 2001
Acyl-CoA:cholesterol acyltransferase inhibition reduces atherosclerosis in apolipoprotein E-deficient miceJ Kusunoki, D K Hansoty, K Aragane, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|January 15, 2000
Postprandial hyperlipidemia in streptozotocin-induced diabetic rats is due to abnormal increase in intestinal acyl coenzyme A:cholesterol acyltransferase activityJ Kusunoki, K Aragane, T Kitamine, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Brain Research. Cognitive Brain Research|October 1, 1993
Chronometrical analysis of event-related potentials and reaction time in patients with multiple lacunar infarctsH Tachibana, K Toda, K Aragane, et al.
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica|March 21, 1998
[Effect of F-1394, a potent and selective inhibitor of acyl-CoA:cholesterol acyltransferase (ACAT), on esterification of cholesterol and basolateral secretion of cholesteryl ester in Caco-2 cells]J Kusunoki, K Aragane, T Kitamine, et al.
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|April 1, 1997
[Hypolipidemic action of F-1394, an acyl-CoA: cholesterol acyltransferase (ACAT) inhibitor, in high-fat diet fed beagle dogs]J Kusunoki, K Aragane, T Kitamine, et al.
Atherosclerosis|August 14, 2001
Effect of F-1394, an acyl-CoA:cholesterol acyltransferase inhibitor, on atherosclerosis induced by high cholesterol diet in rabbitsK Aragane, K Kojima, K Fujinami, et al.
Japanese Journal of Pharmacology|May 21, 1998
Effects of F-1394, an acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor, on ACAT activity in HepG2 cells and on hepatic secretion of lipids in Triton WR-1339-induced hyperlipidemic rats: possible role of hepatic ACAT in very low density lipoprotein secretionK Aragane, J Kusunoki, T Kitamine, et al.
Lancet (London, England)|December 10, 1999
Fever, cough, and nodules on anklesK Aragane, N Akao, T Matsuyama, et al.
Japanese Journal of Pharmacology|September 1, 1995
Hypocholesterolemic action and prevention of cholesterol absorption via the gut by F-1394, a potent acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor, in cholesterol diet-fed ratsJ Kusunoki, K Aragane, T Kitamine, et al.
British Journal of Pharmacology|August 7, 2001
Direct effect of an acyl-CoA:cholesterol acyltransferase inhibitor, F-1394, on atherosclerosis in apolipoprotein E and low density lipoprotein receptor double knockout miceT Chiwata, K Aragane, K Fujinami, et al.
Circulation|May 31, 2001
Acyl-CoA:cholesterol acyltransferase inhibition reduces atherosclerosis in apolipoprotein E-deficient miceJ Kusunoki, D K Hansoty, K Aragane, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|January 15, 2000
Postprandial hyperlipidemia in streptozotocin-induced diabetic rats is due to abnormal increase in intestinal acyl coenzyme A:cholesterol acyltransferase activityJ Kusunoki, K Aragane, T Kitamine, et al.
Pageof 3